Last updated: February 4, 2026
What is the current status of clinical trials for Trilostane?
As of 2023, Trilostane remains primarily used in veterinary medicine, with limited ongoing human trials. Its application in humans is investigational, with no publicly registered clinical trials in major databases such as ClinicalTrials.gov since 2019. The drug’s primary indication in veterinary practice involves treatment of hyperadrenocorticism (Cushing’s disease) in dogs.
In the veterinary sector, Trilostane has established approval and is marketed by companies like Dechra Pharmaceuticals. Trials focused on dosage optimization, safety, and efficacy continue informally through post-market surveillance rather than through formal clinical studies.
How has the market for Trilostane evolved?
Veterinary Market
The veterinary market for Trilostane in 2022 was valued at approximately $150 million globally. North America accounted for about 55%, Europe 25%, and the rest of the world 20%. Growth drivers include increased demand for canine health management, rising pet ownership, and expanded awareness of Cushing’s disease in dogs.
Dechra Pharmaceuticals holds roughly 70% of this market share for veterinary Trilostane. The product faces minimal competition from other drugs because alternatives like mitotane target the same condition but have different safety profiles and administration complications.
Human Market
The human market remains undeveloped. No FDA approval exists for Trilostane in human medicine, limiting its usage primarily to experimental and off-label applications. It is occasionally used in clinical research to evaluate adrenal tumors, but such use is sparse and not commercially significant.
Regulatory Landscape
In the U.S., Trilostane lacks FDA approval. The European Medicines Agency (EMA) has not authorized its human use, but veterinary approval exists in multiple countries including the UK, Germany, and France.
What are the projections for Trilostane’s market growth?
Veterinary Sector
The veterinary pharmaceutical market for endocrinology drugs, including Trilostane, is projected to grow at a compound annual growth rate (CAGR) of approximately 6% from 2022 to 2027. The key factors include:
- Increasing pet adoption rates, particularly in North America and Europe.
- Growing awareness and diagnosis of Cushing’s disease in dogs.
- Expansion of veterinary specialty clinics offering advanced treatments.
Dechra aims to expand Trilostane's application to other endocrine disorders, which could further bolster sales.
Human Sector
The global market for adrenal cortical hormone drugs is expected to reach $1.2 billion by 2027, growing at a CAGR of around 4%. However, Trilostane's niche status as an investigational drug suggests it will remain marginal unless new clinical data leads to regulatory approval.
Potential future growth hinges on results from ongoing trials for adrenal tumors and hyperaldosteronism, which could pave the way for regulatory submissions in humans. Currently, large-scale human trials are lacking.
What are the competitive dynamics in the Trilostane market?
Veterinary Sector
- Dechra Pharmaceuticals: Dominant player with established distribution channels and a wide veterinarian base.
- Alternative treatments: Mitotane, ketoconazole, and metyrapone serve as competitors but have varying safety and efficacy profiles.
Market differentiation exists through safety, dosing convenience, and cost. Trilostane’s once-daily oral administration is an advantage over some alternatives.
Human Sector
- No direct competitors: Two drugs, metyrapone and ketoconazole, are used off-label for specific adrenal conditions.
- Potential entrants: Any future regulatory approval would introduce competition from existing adrenal hormone modulators.
What are the key challenges and opportunities?
Challenges
- Lack of recent formal human clinical trials limits market expansion.
- Regulatory hurdles in achieving approval for human use.
- Competition from established drugs with long safety records in endocrine therapy.
Opportunities
- Positive clinical data could lead to regulatory submissions.
- Broadening veterinary indications, such as treatment of adrenal tumors or other endocrine disorders.
- Strategic partnerships for cross-sector R&D to accelerate human application.
What are the key takeaways?
- Trilostane is well established in veterinary medicine, with steady growth driven by pet ownership trends and increased awareness of endocrine disorders.
- Growth in the veterinary market is moderate, with projections suggesting a CAGR of ~6% through 2027.
- The human therapeutic market remains uncharted for Trilostane; potential depends on clinical trial outcomes.
- Limited recent clinical data raises uncertainty about future approval prospects in humans.
- Competition remains low in veterinary use but high barriers exist for human application without regulatory approval.
FAQs
1. What conditions does Trilostane treat in animals?
It treats hyperadrenocorticism (Cushing’s disease) in dogs, reducing cortisol production.
2. Are there any ongoing clinical trials for Trilostane in humans?
No significant human trials have been registered since 2019, limiting current human development.
3. What are the main competitors to Trilostane in veterinary medicine?
Mitotane and ketoconazole are primary alternatives, used to treat similar conditions with different safety profiles.
4. What regulatory approvals does Trilostane currently hold?
Approved for veterinary use in Europe, North America, and Asia. No FDA approval exists for human use.
5. What future markets could emerge for Trilostane?
Expansion into broader veterinary endocrine applications, conditional on new clinical data. Human markets depend on successful clinical trials and regulatory clearance.
References
- [1] ClinicalTrials.gov. (n.d.). Trilostane clinical trials.
- [2] Dechra Pharmaceuticals Annual Report 2022.
- [3] Global Veterinary Endocrinology Drugs Market Report 2022-2027.
- [4] European Medicines Agency (EMA). Veterinary drug approvals.
- [5] MarketWatch. Veterinary pharmaceuticals industry insights.
